91826-96-9

Basic information

• Product Name: Alanine, N-(methoxycarbonyl)-2-methyl- (9CI)
• Synonyms: Alanine, N-(methoxycarbonyl)-2-methyl- (9CI);N-(methoxycarbonyl)-2-methylAlanine;2-((METHOXYCARBONYL)AMINO)-2-METHYLPROPANOIC ACID
• CAS NO: 91826-96-9
• Molecular Formula: C₆H₁₁NO₄
• Molecular Weight: 161.15584
• Product Categories: GLYCINESCAFFOLD
• Mol File: 91826-96-9.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Alanine, N-(methoxycarbonyl)-2-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Alanine, N-(methoxycarbonyl)-2-methyl- (9CI)(91826-96-9)
• EPA Substance Registry System: Alanine, N-(methoxycarbonyl)-2-methyl- (9CI)(91826-96-9)

Safety Data

• Hazardous Substances Data: 91826-96-9(Hazardous Substances Data)

Upstream product

• 62-57-7 2-Aminoisobutyric acid 
• 79-22-1 methyl chloroformate 
• 5839-88-3 4,4-dimethyloxazolidine-2,5-dione 
• 124-41-4 sodium methylate 

Downstream Products

• 85612-23-3 benzyl 1-(N-methoxycarbonyl-α-methylalanyl)-3-indolepropionate 
• 916072-89-4 Naldemedine 
• 1345728-04-2 17-(cyclopropylmethyl)-6,7-didehydro-4,5H-epoxy-3,6,14-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-7-carboxamide 4-methylbenzenesulfonic acid tosylate 
• 1374774-70-5 C₃₄H₃₆N₄O₇ 
• 1374817-07-8 C₁₃H₁₅N₃O₃ 
• 85612-21-1 N-methoxycarbonyl-α-methylalanine p-nitrophenyl ester 
• 5839-88-3 4,4-dimethyloxazolidine-2,5-dione 

Relevant articles and documents

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HCV replication.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.